Show Notes
Our guest this week is Michael Thurn the CEO and Managing Director of PharmAust, a clinical-stage biotechnology company. He tells us about Monepantel which is a well-known veterinary drug. It has been shown to have an effect on the abnormal accumulation of protein in cells. This accumulation is associated with motor neurone disease. Monepantel works by increasing the recycling and removal of excessive or abnormal proteins. Results from phase 1 of this trial suggest that monepantel was well tolerated. In fact it showed a slowing in progression of MND. In July of 2024 Monepantel has been included in the Healy ALS trials, in Boston, USA, which means the study will be fast tracked. To learn more about the studies please go to https://www.pharmaust.com
More from Let's Talk MND
In this episode, Peta Hardy, an Occupational Therapist who specialises in MND, and shares insights on how occupational therapy supports individuals with MND. She discusses assistive technology, home safety, and the importance of a multidisciplinary team to improve quality of life.
In this mind blowing episode, Dr. Amanda Wright and Dr. Lyndal Henden discuss their recent research findings that MND has a 7 times higher prevalence in areas of in Western NSW, compared with the rest of the world! We explore incidence rates, genetics and environmental factors, and the challenges of rural healthcare. They share insights into ongoing efforts to improve data collection, diagnosis, and care for rural patients.
What happens when you live with MND far longer than expected?
Adam Dowling is living with SOD1 MND, a rare genetic form of motor neurone disease.
In this episode, I’m joined by Sarah Shuttlewood, who shares her family’s journey following her father Peter’s diagnosis with MND.